Patent Application
20240166591
This application is related to a new method of preparing cannabinoid acid esters directly from selected plant material of the genus Cannabis sp, preferably Cannabis sativa, by simultaneously extracting the cannabinoid acids and synthesizing their respective esters during the extraction process. In addition, the application concerns pharmaceutical preparations containing cannabinoid acid esters, directly obtained from the above method and their use for the production of therapeutic preparations. The application concerns the field of medicine and pharmacy.
The Cannabis sp plant, preferably Cannabis sativa, contains terpenophenolic compounds called cannabinoids. Cannabinoids refer to the compounds that interact and bind to the cannabinoid receptors CB1 and CB2. Compounds that bind to cannabinoid receptors are endocannabinoids, phytocannabinoids and synthetic cannabinoids. Cannabinoid acid refers to the carboxylic acid substituted cannabinoid. Cannabinoid acid ester refers to the ester form of cannabinoid acids, where the ester substituent is attached to the carboxylic group of cannabinoid acid.
In the plant are mainly present cannabinoid acids with general formula I, II, III, IV with R1=H.
Cannabidiolic acid (CBDA) (I), cannabigerolic acid (CBGA) (II) and cannabichromenic acid (CBCA) (III) are the main non-psychotropic phytocannabinoids of Cannabis sativa, and tetrahydrocannabinolic acid (THCA), corresponding to formula IV, is the main psychoactive substance of C. sativa, where with selected plant material and with a suitable way of extraction, the extract can contain up to 80% of these substances. Cannabinoid acids are considered precursors of the neutral cannabinoids, such as cannabigerol (CBG) which can be produced by decarboxylation of cannabigerolic acid. Due to the instability of cannabinoids, their chemical form has been studied for the first time in the past with the methyl ester analysis of each cannabinoid (Mechoulam & Gaoni; Tetrahedron. 1965 May;21(5):1223-9).
The glandular hairs of the inflorescences of the plant Cannabis sp. preferably, Cannabis sativa, contain the highest percentage of phytocannabinoids. Cultivar varieties mainly, contain CBDA and/or CBGA and/or CBCA and/or THCA.
CBDA, CBGA, CBCA and THCA have been evaluated for their anti-cancer activity and their results are part of US2020030282 A1 Patent Application. CBDA has been shown to inhibit cell migration and enhance the expression of cyclooxygenase-2 in breast cancer cells MDA-MB-231 (Hirao-Suzuki et al.; J Toxicol Sci. 2020; 45 (4): 227-236, Hirao-Suzuki et al., Nat Prod Commun. 2017 May; 12 (5): 759-761. Takeda et al.; Toxicol Lett. 2012 Nov 15; 214 (3): 314-9).
However, the activity of acids is higher in in vitro experiments than in in vivo experiments, due to the reduced lipophilicity of cannabinoid acids, which leads to limited penetration into biological membranes (Smeriglio et al.; Fitoterapia. 2018 June; 127: 101-8). The inventors of their experiments know that by creating esters, the molecules become more lipophilic with increased penetrating capability, which may contribute to increasing their activity. The general types of cannabinoid esters are:
R1 consists of a straight or branched alkyl group, alkenyl group or alkynyl group having from C1 to C5 carbons.
For cannabinoid acid methyl esters there are published synthesis methods, for example in WO2019033164 A1 and EP2913321 A1. However, the published synthesis methods require chromatographic purification of the substances before and after the esterification, which makes the process quite complicated, while increases the cost of the final products.
CBDA esters have been studied in various pharmacological targets e.g., based on the application of WO2020186010 A1, but never so far for their anti-cancer properties, while the esters of CBGA, CBCA and THCA have never been pharmacologically evaluated. In the present invention the above esters were evaluated and for the first time significant anti-cancer activity was found.
The synthesis of the esters described in the present invention involves the simultaneous extraction and esterification of the substances from the C. sativa plant, as the solvent used for the extraction simultaneously leads to the esterification. This process is original and at the same time more economical and less time consuming than the synthesis methods mentioned in the literature, without requiring chromatographic purification of the substances. The novelty is in particular the fact that the esterification reagents, 4-dimethylaminopyridine (DMAP) or pyridine or triethylamine or any other tertiary nitrogenous base and 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) or N,N′-Diisopropylcarbodiimide or any other conjugating agent with hydrophilic by-products, are not inhibited by the other components of the plant material and at the same time the resulting product can be easily separated from the other components of the plant material without the need for chromatography. In contrast, the use of standard N,N′-Dicyclohexylcarbodiimide (DCC) coupling reagent is not appropriate as it does not produce hydrophilic by-products and therefore requires the use of chromatography to purify cannabinoids.
Therefore, an easier and faster way of extraction and synthesis of cannabinoid esters can lead to a wider pharmacological investigation of these substances and consequently to an easier production of pharmaceutical compositions consisting of cannabinoid acid esters.
According to one embodiment, the present invention relates to a process for the production of esters from the corresponding cannabinoid acids during the simultaneous extraction of the cannabinoid acids from the C. sativa plant.
In another embodiment, the invention relates to cannabinoid acid esters of general formula I or II or III or IV, readily obtained from the method mentioned above.
In a further embodiment, the invention relates to cannabinoid acid esters of general formula I or II or III or IV for use in the treatment of cancer.
In yet another embodiment, the invention relates to cannabinoid acid esters of general formula I or II or III or IV for use in the treatment of psoriasis.
In another embodiment, the invention relates to cannabinoid acid esters of general formula I or II or III or IV for use in the treatment of degenerative diseases of the central nervous system.
In another embodiment, the invention relates to cannabinoid acid esters of general formula I or II or III or IV for use in the treatment of chronic pain.
In yet another embodiment, the invention relates to pharmaceutical compositions comprising cannabinoid acid esters of general formula I or II or III or IV.
The present invention and its various embodiments refer to a novel process for the production of cannabinoid acid esters of general formula I or II or III or IV, wherein R1 consists of a straight or branched alkyl group, alkenyl group or alkynyl group having from 1 to 5 carbons, preferably from 3 to 5 carbons, during the simultaneous extraction of cannabinoid acids derived from the plant Cannabis sp., Preferably Cannabis sativa, into esters of cannabinoid acids with general formula I or II or III or IV prepared by this particular method, and pharmaceutical compositions containing esters of cannabinoid acids of general formula I or II or III or IV for use in medical treatment.
More specifically, in one embodiment, the present invention relates to a process for the production of esters from the corresponding cannabinoid acids during the simultaneous extraction of the cannabinoid acids from the C. sativa plant.
In another embodiment, the invention relates to cannabinoid acid esters of general formula I or II or III or IV, wherein R1 consists of a straight or branched alkyl group, alkenyl group or alkynyl group having from 1 to 5 carbons, preferably from 3 to 5 carbons, readily obtained from the method mentioned above.
In a further embodiment, the invention relates to cannabinoid acid esters of general formula I or II or III or IV for use in the treatment of cancer, preferably breast cancer.
In yet another embodiment, the invention relates to cannabinoid acid esters of general formula I or II or III or IV for use in the treatment of psoriasis.
In another embodiment, the invention relates to cannabinoid acid esters of general formula I or II or III or IV for use in the treatment of degenerative diseases of the central nervous system.
In another embodiment, the invention relates to cannabinoid acid esters of general formula I or II or III or IV for use in the treatment of chronic pain.
In yet another embodiment, the invention relates to pharmaceutical compositions comprising cannabinoid acid esters of general formula I or II or III or IV, as obtained by the method mentioned above.
In another embodiment, the invention relates to pharmaceutical compositions comprising cannabinoid acid esters of general formula I or II or III or IV in the form of an oral solution, solution for injection, transdermal solution, suppository or tablet.
In yet another embodiment, the invention relates to pharmaceutical compositions comprising cannabinoid acid esters of general formula I or II or III or IV and one or more pharmaceutically acceptable excipients.
According to some embodiments the pharmaceutically acceptable excipient is an aqueous solution or carrier. In some embodiments the aqueous solution is a buffer at normal pH or near normal, such as Phosphate Buffer Saline (PBS). In some embodiments the pharmaceutically acceptable excipient may be an emulsifier, a buffering agent, a pH adjusting agent, a tonic modifier, a preservative, an antioxidant, a stabilizer or a combination of the above.
Although the present invention is described with reference to specific embodiments thereof, it will be appreciated by one skilled in the field, that various variations may be made and equivalent alternatives may be used without departing from the scope and scope of the invention. The same is true of the following examples which are used to illustrate in practice and clearly ways of carrying out the invention and not to limit it.
The first part of the invention presents the synthesis of cannabinoid acid esters with general formula I or II or III or IV from the corresponding cannabinoid acids during the simultaneous extraction of cannabinoid acids from selected plant material of C. sativa.
The plant material used for the extraction includes the inflorescences and the glandular hairs of the plant C. sativa. The synthesis of each ester is carried out in parallel with the extraction, using a different alcoholic extraction solvent. The extraction medium is also a reagent for the synthesis of esters and the R1 substituent is determined by the solvent to be used for the extraction. The solvent may be any straight or branched alcohol having carbon numbers from 1 to 5. Preferably the solvent is a primary or secondary alcohol, in liquid phase and at room temperature. The extraction of the plant material is carried out in an ultrasonic bath. This method of extraction is very efficient and at the same time favours the formation of esters. The same procedure can be performed without an ultrasonic bath, with stirring and with or without heating of the solvent but with reduced extraction efficiency and consequently with reduced reaction efficiency. In this case, despite the lower efficiency, the process may be preferred due to lower cost and large-scale applicability. The extraction is carried out in the presence of the reagents 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and 4-dimethylaminopyridine (DMAP), which are used to synthesize the esters.
The reagents (EDC and DMAP) added during the extraction to the ester composition give hydrophilic by-products, which are water-soluble and remain insoluble in organic solvents.
Purification of the extract from the by-products of the reaction occurring in parallel with the extraction is performed by changing the pH of the extract and then by rinsing with water, without the need of chromatographic purification to obtain the final product.
The simultaneous extraction and production of cannabinoid acid esters from the Cannabis sativa plant involves the following steps:
To 1.5 g of C. sativa plant material with a CBGA content of 30% by dry weight 150 ml of methanol are added. 1.25 mmol DMAP and 2.5 mmol EDC are added to the mixture. The mixture is placed in an ultrasonic bath for 25 minutes. The mixture is then filtered to remove the plant material and the methanol is obtained. To the solution are added 50 ml of 0.5M HCl solution. Then, 50 ml of hexane are added forming a two-phase solvent system and the hexane phase (organic) containing the CBGA-Me is obtained. The organic phase is rinsed with saturated sodium bicarbonate solution and water. The organic phase is evaporated to dryness to obtain 441.2 mg of CBGA-Me. 1H-NMR (400 MHz, CDCl3): 6.28 (1H, s), 5.28 (1H, t, 7.0 Hz), 5.07 (1H, t, 6.6 Hz), 3.92 (3H, s), 3.42 (2H, d, 7.0Hz), 2.09 (2H, t, 6.6 Hz), 2.09 (2H, q, 6.5 Hz), 2.81 (2H, t, 7.6 Hz), 2.07 (2H, m), 1.81 (3H, s), 1.67 (3H, s), 1.59 (3H, s), 1.35 (2H, m), 1.35 (2H, m), 0.90 (3H, t, 6.9 Hz).
To 1.5 g of C. sativa plant material with a CBGA content of 30% by dry weight 150 ml of ethanol is added. 1.25 mmol DMAP and 2.5 mmol EDC are added to the mixture. The mixture is placed in an ultrasonic bath for 30 minutes. The mixture is then filtered to remove the plant material and the ethanol is taken up. To the solution is added 50 ml of 0.5M HCl solution. Then, 50 ml of hexane are added and a biphasic solvent system is formed and the hexane phase containing the CBGA-Et is obtained. The organic phase is rinsed with saturated sodium bicarbonate solution and water. The organic phase is evaporated to dryness to obtain 458.3 mg CBGA-Et. 1H-NMR (400 MHz, CDCl3): 6.28 (1H, s), 5.28 (1H, t, 7.0 Hz), 5.07 (1H, t, 6.6 Hz), 4.39 (2H, q, 7.1 Hz), 3.41 (2H), d, 7.0Hz), 2.09 (2H, t, 6.6 Hz), 2.09 (2H, q, 6.5 Hz), 2.82 (2H, t, 7.6 Hz), 2.07 (2H, m), 1.81 (3H, s), 1.67 (3H, s), 1.59 (3H, s), 1.40 (3H, t, 7.1 Hz), 1.35 (2H, m), 1.35 (2H, m), 0.90 (3H, t, 6.9 Hz).
To 1.5 g of C. sativa plant material with a CBDA content of 30% by dry weight 150 ml of methanol is added. 1.25 mmol DMAP and 2.5 mmol EDC are added to the mixture. The mixture is placed in an ultrasonic bath for 25 minutes. The mixture is then filtered to remove the plant material and the methanol is taken up. To the solution is added 50 ml of 0.5M HCl solution. ‘Then, 50 ml of hexane are added and a biphasic solvent system is formed and the hexane phase containing the CBDA-Me is obtained. The organic phase is rinsed with saturated sodium bicarbonate solution and water. The organic phase is evaporated to dryness to obtain 444.6 mg CBDA-Me. 1H-NMR (400 MHz, CDCl3): 6.23 (1H, s), 5.57 (1H, s), 4.53 (1H, m), 4.23 (1H, m), 4.11 (1H, m), 3.92 (3H, s)), 2.93 (1H, m), 2.83 (1H, m), 2.40 (m), 2.21 (1H, m), 2.10 (1H, m), 1.86 (m), 1.81 (3H, s), 1.72 (3H, s), 1.57 (2H, m), 1.35 (8H, m), 0.89 (3H, t, 6.9 Hz).
To 1.5 g of C. sativa plant material with a CBDA content of 30% by dry weight ml of ethanol are added. 1.25 mmol DMAP and 2.5 mmol EDC are added to the mixture. The mixture is placed in an ultrasonic bath for 25 minutes. The mixture is then filtered to remove the plant material and the ethanol is taken up. To the solution is added 50 ml of 0.5M HCl solution. ‘Then, 50 ml of hexane are added to form a biphasic solvent system and the hexane phase containing the CBDA-Et is obtained. The organic phase is rinsed with saturated sodium bicarbonate solution and water. The organic phase is evaporated to dryness to obtain 459.7 mg CBDA-Et. 1H-NMR (400 MHz, CDCl3): 6.28 (1H, s), 5.28 (1H, t, 7.0 Hz), 5.07 (1H, t, 6.6 Hz), 4.39 (2H, q, 7.1 Hz), 3.41 (2H), d, 7.0Hz), 2.09 (2H, t, 6.6 Hz), 2.09 (2H, q, 6.5 Hz), 2.82 (2H, t, 7.6 Hz), 2.07 (2H, m), 1.81 (3H, s), 1.67 (3H, s), 1.59 (3H, s), 1.40 (3H, t, 7.1 Hz), 1.35 (2H, m), 1.35 (2H, m), 0.90 (3H, t, 6.9 Hz).
To 1.5 g of C. sativa plant material with a CBGA content of 30% by dry weight 150 ml of isopropanol is added. 1.25 mmol DMAP and 2.5 mmol EDC are added to the mixture. The mixture is placed in an ultrasonic bath for 40 minutes. The mixture is then filtered to remove plant material and isopropanol is obtained. To the solution is added 50 ml of 0.5M HCl solution. Then, 50 ml of hexane are added and a two-phase solvent system is formed and the hexane phase containing the CBGA-iPro is obtained. The organic phase is rinsed with saturated sodium bicarbonate solution and water. The organic phase is evaporated to dryness to obtain 451.2 mg CBGA-iPro. 1H-NMR (400 MHz, CDCl3): 6.24 (1H, s), 5.33 (1H, m), 5.28 (1H, t, 7.0 Hz), 5.07 (1H, t, 6.6 Hz), 3.92 (3H, s), 3.43 (2H, d, 7.0Hz), 2.09 (2H, t, 6.6 Hz), 2.09 (2H, q, 6.5 Hz), 2.83 (2H, t, 7.6 Hz), 2.07 (2H, m), 1.81 (3H, s), 1.67 (3H, s), 1.59 (3H, s), 1.35 (2H, m), 1.41 (3H, s), 1.39 (3H, s), 1.35 (2H, m), 0.90 (3H, t, 6.9 Hz).
To 1.5 g of C. sativa plant material with a CBCA content of 6% by dry weight 150 ml of methanol is added. To the mixture are added 0.25 mmol DMAP and 0.5 mmol EDC. The mixture is placed in an ultrasonic bath for 25 minutes. The mixture is then filtered to remove the plant material and the methanol is taken up. To the solution is added 50 ml of 0.5M HCl solution. ‘Then, 50 ml of hexane are added and a biphasic solvent system is formed and the hexane phase containing the CBCA-Me is obtained. The organic phase is rinsed with saturated sodium bicarbonate solution and water. The organic phase is evaporated to dryness to obtain 84 mg CBCA-Me. 1H-NMR (400 MHz, CDCl3): 6.74 (1H, d, 10.1 Hz), 6.23 (1H, s), 5.48 (1H, d, 10.1 Hz), 5.21 (1H, m), 3.93 (3H, s), 2.81 (2H, t, 6.9 Hz), 1.95 (2H, m), 1.67 (3H, s), 1.59 (3H, s), 1.55 (2H, m), 1.41 (3H, s), 0.9 (3H, m), 1.55 (2H, m), 1.32 (4H, m).
To 1.5 g of C. sativa plant material with a THCA content of 30% by dry weight 150 ml of ethanol is added. 1.25 mmol DMAP and 2.5 mmol EDC are added to the mixture. The mixture is placed in an ultrasonic bath for 30 minutes. The mixture is then filtered to remove the plant material and the ethanol is taken up. To the solution is added 50 ml of 0.5M HCl solution. ‘Then, 50 ml of hexane are added and a two-phase solvent system is formed and the hexane phase containing the THCA-Et is obtained. The organic phase is rinsed with saturated sodium bicarbonate solution and water. The organic phase is evaporated to dryness to obtain 458 mg THCA-Et. 1H-NMR (400 MHz, CDCl3): 6.41 (1H, brs), 6.22 (1H, s), 4.41 (2H, 7.1 Hz), 3.23 (1H, dm, 10.9 Hz), 2.89 (1H, m), 2.74 (1H, m), 2.18 (2H, m), 1.93 (1H, m), 1.68 (3H, s), 1.67 (m), 1.57 (2H, m), 1.44 (3H, s), 1.42 (3H, t, 7.1 Hz), 1.35 (4H, m), 1.11 (3H, s), 0.90 (3H, t, 6.9 Hz)
The CBGA methyl ester from Example 1 (1000 mg) is dissolved in olive oil (20 grams) and placed in a vial with dropper for use as an oral solution in drops.
The final product of the concentrate from any of Examples 1a-1d is mixed with olive oil in a ratio of 1:10 by weight and incorporated into a soft capsule.
The final product of the concentrate from any of Examples 1a-1d is mixed with microcrystalline cellulose in a ratio of 1:20 by weight and can be used to make hard capsules.
The cytotoxic activity of CBDA methyl esters, CBCA CBGA and THCA was studied by the in vitro MTT colorimetric process (Mosmann, T. et al. J. Immunol. Methods. 1983; 65: 55-63). This method, which is widely used to measure cellular metabolic activity as an indicator of cell viability, division and cytotoxicity, is based on the reduction of a yellow salt of tetrazole ((3-(4,5-dimethylthiazol-2-yl)-2). 5-diphenyltetrazolium bromide or MTT) in violet formazan crystals from metabolically active cells.
Briefly for this cytotoxicity test, the SK-BR-3 cancer cell line (human breast cancer cell line), the MCF-7 cancer cell line (human breast cancer cell line), and the A2058 cancer cell line (series) were used. melanoma) and the cancer line SKMEL28 (melanoma line). All cell lines were tested at 20% v/v O2, in the presence of 10% FBS after 48 h or 72 h of incubation.
The study of the cytotoxic activity of CBGA, CBCA and THCA CBDA methyl esters by the MTT assay showed that substances in concentrations less than 40 μM can lead to cell death in 50% of SK-cancer cells. BR-3 MCF7, A2058 and SKMEL28 and therefore these substances and any medicinal products derived from them can be used to treat breast cancer and melanoma.
In the SKBR3 series, the greatest activity was shown by CBGA methyl ester, which for example had much better activity than CBDA methyl ester at 48 h and 72 h (
In comparison, the action of esters is much stronger than the known corresponding decarboxylated products. For example, CBGA methyl ester is almost twice as active as CBG at 72 h. Specifically, in cancer cell line SKBR3 oCBGA-Me has EC50 =20.2 pM while CBG has EC50=38.8 μM.
The esters also have a much stronger effect on SK-BR-3 cancer cells than normal MCF10A cells as shown in
In MCF7 cell line CBGA methyl ester showed EC50 activity=18 μM.
Regarding the two melanoma cancer lines, CBGA methyl ester showed EC50=17 μM.
The improved activity and lipophilicity of esters, in relation to their carboxylated and decarboxylated analogues having a number of known actions such as protection against neurodegenerative diseases, which makes them potentially effective in all therapeutic applications of cannabinoids.
| Number | Date | Country | Kind |
|---|---|---|---|
| 20210100041 | Jan 2021 | GR | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2022/051402 | 1/21/2022 | WO |
